CureVac NV Ownership
| CVAC Stock | USD 2.87 0.13 4.74% |
Shares in Circulation | First Issued 2019-03-31 | Previous Quarter 224.3 M | Current Value 225.4 M | Avarage Shares Outstanding 193 M | Quarterly Volatility 20.1 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
CureVac |
CureVac Stock Ownership Analysis
About 45.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.85. Some equities with similar Price to Book (P/B) outperform the market in the long run. CureVac NV has Price/Earnings To Growth (PEG) ratio of 0.07. The entity had not issued any dividends in recent years. CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid . The company was founded in 2000 and is headquartered in Tbingen, Germany. Curevac NV operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 764 people. For more info on CureVac NV please contact LLM LLM at 49 7071 9883 0 or go to https://www.curevac.com.Besides selling stocks to institutional investors, CureVac NV also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different CureVac NV's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align CureVac NV's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
CureVac NV Quarterly Liabilities And Stockholders Equity |
|
About 45.0% of CureVac NV are currently held by insiders. Unlike CureVac NV's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against CureVac NV's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of CureVac NV's insider trades
CureVac Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as CureVac NV is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading CureVac NV backward and forwards among themselves. CureVac NV's institutional investor refers to the entity that pools money to purchase CureVac NV's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Swiss National Bank | 2024-09-30 | 198.5 K | Walleye Trading Advisors, Llc | 2024-06-30 | 187.9 K | Deutsche Bank Ag | 2024-06-30 | 151 K | Susquehanna International Group, Llp | 2024-06-30 | 150.6 K | Freestone Capital Holdings, Llc | 2024-06-30 | 139.6 K | Legal & General Group Plc | 2024-06-30 | 119 K | Boothbay Fund Management, Llc | 2024-09-30 | 113.2 K | Ubs Group Ag | 2024-06-30 | 113 K | Norges Bank | 2024-06-30 | 110.9 K | Millennium Management Llc | 2024-06-30 | 2.9 M | Blackrock Inc | 2024-06-30 | 2.3 M |
CureVac NV Outstanding Bonds
CureVac NV issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. CureVac NV uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most CureVac bonds can be classified according to their maturity, which is the date when CureVac NV has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
CureVac NV Corporate Filings
6K | 12th of November 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
| 25th of April 2024 Other Reports | ViewVerify | |
13A | 14th of February 2024 An amended filing to the original Schedule 13G | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether CureVac NV offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of CureVac NV's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Curevac Nv Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Curevac Nv Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CureVac NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade CureVac Stock refer to our How to Trade CureVac Stock guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CureVac NV. If investors know CureVac will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CureVac NV listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.49 | Revenue Per Share 0.294 | Quarterly Revenue Growth 0.905 | Return On Assets (0.25) | Return On Equity (0.54) |
The market value of CureVac NV is measured differently than its book value, which is the value of CureVac that is recorded on the company's balance sheet. Investors also form their own opinion of CureVac NV's value that differs from its market value or its book value, called intrinsic value, which is CureVac NV's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CureVac NV's market value can be influenced by many factors that don't directly affect CureVac NV's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CureVac NV's value and its price as these two are different measures arrived at by different means. Investors typically determine if CureVac NV is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CureVac NV's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.